CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
67 hedge funds and large institutions have $27.5M invested in CTI BioPharma Corp. (DE) Common Stock in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 21 reducing their positions, and 32 closing their positions.
16% less funds holding
Funds holding: 80 → 67 (-13)
41% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 32
52% less capital invested
Capital invested by funds: $57.4M → $27.5M (-$29.9M)
52% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 21
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$889K |
| 2 |
Goldman Sachs
New York
|
+$629K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$536K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$395K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
+$235K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.66M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.74M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.99M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.2M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.02M |
CTIC Hedge Fund Activity: Q2 2016 in Review
67 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q2 2016, worth a combined $27.5M — down 52% from $57.4M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CTIC and 19 opened new positions — a net loss of 13 holders — while 21 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $889K. The largest seller was Fidelity Investments, cutting an estimated $5.66M.
- 67 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q2 2016, down from 80 in Q1 2016.
- Funds reported $27.5M of CTI BioPharma Corp. (DE) Common Stock stock for Q2 2016, down 52% quarter-over-quarter.
- 19 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q2 2016 and 32 closed out, a net change of -13 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q2 2016 was Millennium Management, an estimated $889K added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q2 2016 was Fidelity Investments, an estimated $5.66M sold.
Based on aggregated 13F filings for Q2 2016.